{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:05:07Z","timestamp":1789556707939,"version":"build-2803163510"},"reference-count":33,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Scandinavian Journal of Rheumatology"],"DOI":"10.1080\/03009742.2026.2722526","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:33:52Z","timestamp":1789554832000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of tofacitinib in polymyalgia rheumatica: a retrospective comparative study"],"prefix":"10.1080","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6556-2548","authenticated-orcid":false,"given":"X","family":"Wang","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital)","place":["Wuhu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8379-1423","authenticated-orcid":false,"given":"D","family":"Feng","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital)","place":["Wuhu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3372-7985","authenticated-orcid":false,"given":"L","family":"Jia","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital)","place":["Wuhu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5520-8747","authenticated-orcid":false,"given":"L","family":"Xu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital)","place":["Wuhu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"5","key":"e_1_3_5_2_1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/joim.13525","article-title":"An update on polymyalgia rheumatica","volume":"292","author":"Lundberg IE","year":"2022","unstructured":"Lundberg IE, Sharma A, Turesson C, et al. An update on polymyalgia rheumatica. J Intern Med. 2022;292(5):717\u2013732.","journal-title":"J Intern Med"},{"issue":"2","key":"e_1_3_5_3_1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/rheumatology\/keae569","article-title":"A history of polymyalgia rheumatica: a narrative review","volume":"64","author":"Shah S","year":"2025","unstructured":"Shah S, Rao S, Mackie SL, et al. A history of polymyalgia rheumatica: a narrative review. Rheumatology. 2025;64(2):470\u2013476.","journal-title":"Rheumatology"},{"key":"e_1_3_5_4_1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bcp.2019.03.027","article-title":"Treatment of polymyalgia rheumatica","volume":"165","author":"Casta\u00f1eda S","year":"2019","unstructured":"Casta\u00f1eda S, Garc\u00eda-casta\u00f1eda N, Prieto-Pe\u00f1a D, et al. Treatment of polymyalgia rheumatica. Biochem Pharmacol. 2019;165:221\u2013229.","journal-title":"Biochem Pharmacol"},{"issue":"21","key":"e_1_3_5_5_1","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.3390\/jcm13216492","article-title":"Traditional and emerging strategies for managing polymyalgia rheumatica: insights into new treatments","volume":"13","author":"Garc\u00eda-Porr\u00faa C","year":"2024","unstructured":"Garc\u00eda-Porr\u00faa C, Heras-Recuero E, Bl\u00e1zquez-S\u00e1nchez T, et al. Traditional and emerging strategies for managing polymyalgia rheumatica: insights into new treatments. J Clin Med. 2024;13(21):6492.","journal-title":"J Clin Med"},{"issue":"4","key":"e_1_3_5_6_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray M","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457\u2013465.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"e_1_3_5_7_1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/87551225221116266","article-title":"Complications of corticosteroid therapy: a comprehensive literature review","volume":"38","author":"Koshi EJ","year":"2022","unstructured":"Koshi EJ, Young K, Mostales JC, et al. Complications of corticosteroid therapy: a comprehensive literature review. J Pharm Technol. 2022;38(6):360\u2013367.","journal-title":"J Pharm Technol"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkac034"},{"issue":"10","key":"e_1_3_5_9_1","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/1744666X.2023.2240519","article-title":"Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm?","volume":"19","author":"Ricordi C","year":"2023","unstructured":"Ricordi C, Pipitone N, Marvisi C, et al. Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm? Expert Rev Clin Immunol. 2023;19(10):1195\u20131203.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"e_1_3_5_10_1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ard.2025.11.025","article-title":"Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg\/week in recently diagnosed polymyalgia rheumatica","volume":"85","author":"Bolhuis TE","year":"2026","unstructured":"Bolhuis TE, Nesep K, Marsman DE, et al. Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg\/week in recently diagnosed polymyalgia rheumatica. Ann Rheum Dis. 2026;85(4):761\u2013770.","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"e_1_3_5_11_1","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper","volume":"389","author":"Spiera RF","year":"2023","unstructured":"Spiera RF, Unizony S, Warrington KJ, et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med. 2023;389(14):1263\u20131272.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_5_12_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ard.2025.09.005","article-title":"Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment","volume":"85","author":"Choy EH","year":"2026","unstructured":"Choy EH, Unizony SH, Wells AF, et al. Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment. Ann Rheum Dis. 2026;85(1):6\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"e_1_3_5_13_1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.rdc.2023.03.005","article-title":"Giant cell arteritis and polymyalgia rheumatica: treatment approaches and new targets","volume":"49","author":"Nepal D","year":"2023","unstructured":"Nepal D, Putman M, Unizony S. Giant cell arteritis and polymyalgia rheumatica: treatment approaches and new targets. Rheum Dis Clin North Am. 2023;49(3):505\u2013521.","journal-title":"Rheum Dis Clin North Am"},{"issue":"7","key":"e_1_3_5_14_1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14656566.2026.2668585","article-title":"Targeted small molecules in polymyalgia rheumatica: the emerging role of JAK inhibitors beyond glucocorticoids and DMARDs","volume":"27","author":"Gonz\u00e1lez-Gay MA","year":"2026","unstructured":"Gonz\u00e1lez-Gay MA, \u00c1lvarez-Rubio M, de Benito-Verni\u00e8re A, et al. Targeted small molecules in polymyalgia rheumatica: the emerging role of JAK inhibitors beyond glucocorticoids and DMARDs. Expert Opin Pharmacother. 2026;27(7):611\u2013623.","journal-title":"Expert Opin Pharmacother"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001595"},{"key":"e_1_3_5_16_1","doi-asserted-by":"crossref","first-page":"1759720X2097777","DOI":"10.1177\/1759720X20977777","article-title":"Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib","volume":"13","author":"Chimenti MS","year":"2021","unstructured":"Chimenti MS, Conigliaro P, Biancone L, et al. Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib. Ther Adv Musculoskelet Dis. 2021;13:1759720X20977777.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"e_1_3_5_17_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","article-title":"JAK inhibitors for rheumatoid arthritis","volume":"32","author":"Kubo S","year":"2023","unstructured":"Kubo S, Nakayamada S, Tanaka Y. JAK inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs. 2023;32(4):333\u2013344.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"e_1_3_5_18_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt J","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89.","journal-title":"Arthritis Res Ther"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004249"},{"issue":"4","key":"e_1_3_5_20_1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta B","year":"2012","unstructured":"Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71(4):484\u2013492.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"e_1_3_5_21_1","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/ard.2003.011379","article-title":"A disease activity score for polymyalgia rheumatica","volume":"63","author":"Leeb BF","year":"2004","unstructured":"Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis. 2004;63(10):1279\u20131283.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"e_1_3_5_22_1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/art.22771","article-title":"The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission","volume":"57","author":"Leeb BF","year":"2007","unstructured":"Leeb BF, Rintelen B, Sautner J, et al. The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission. Arthritis Rheum. 2007;57(5):810\u2013815.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"e_1_3_5_23_1","doi-asserted-by":"crossref","first-page":"102995","DOI":"10.1016\/j.autrev.2021.102995","article-title":"Immune system activation in polymyalgia rheumatica: which balance between autoinflammation and autoimmunity? A systematic review","volume":"21","author":"Hysa E","year":"2022","unstructured":"Hysa E, Gotelli E, Sammor\u00ec S, et al. Immune system activation in polymyalgia rheumatica: which balance between autoinflammation and autoimmunity? A systematic review. Autoimmun Rev. 2022;21(2):102995.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"e_1_3_5_24_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","article-title":"Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis","volume":"41","author":"Floris A","year":"2022","unstructured":"Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheumatol. 2022;41(1):19\u201331.","journal-title":"Clin Rheumatol"},{"key":"e_1_3_5_25_1","doi-asserted-by":"crossref","first-page":"738481","DOI":"10.3389\/fimmu.2021.738481","article-title":"Tofacitinib suppresses several JAK-STAT pathways in rheumatoid arthritis in vivo and baseline signaling profile associates with treatment response","volume":"12","author":"Palmroth M","year":"2021","unstructured":"Palmroth M, Kuuliala K, Peltomaa R, et al. Tofacitinib suppresses several JAK-STAT pathways in rheumatoid arthritis in vivo and baseline signaling profile associates with treatment response. Front Immunol. 2021;12:738481.","journal-title":"Front Immunol"},{"issue":"1","key":"e_1_3_5_26_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu X","year":"2021","unstructured":"Hu X, Li J, Fu M, et al. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"e_1_3_5_27_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/03009742.2024.2353433","article-title":"Retention rates of different Janus kinase inhibitors in rheumatoid arthritis: experience from a large monocentric cohort","volume":"53","author":"Farina N","year":"2024","unstructured":"Farina N, Tomelleri A, Boffini N, et al. Retention rates of different Janus kinase inhibitors in rheumatoid arthritis: experience from a large monocentric cohort. Scand J Rheumatol. 2024;53(6):428\u2013432.","journal-title":"Scand J Rheumatol"},{"key":"e_1_3_5_28_1","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2147\/IJGM.S414267","article-title":"Efficacy of JAK inhibitors versus DMARDs in the treatment of polymyalgia rheumatica in China","volume":"16","author":"Gu J","year":"2023","unstructured":"Gu J, Yang M, Zhang B, et al. Efficacy of JAK inhibitors versus DMARDs in the treatment of polymyalgia rheumatica in China. Int J Gen Med. 2023;16:2981\u20132986.","journal-title":"Int J Gen Med"},{"issue":"5","key":"e_1_3_5_29_1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/ard-2022-223562","article-title":"Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study","volume":"82","author":"Zhang L","year":"2023","unstructured":"Zhang L, Li J, Yin H, et al. Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study. Ann Rheum Dis. 2023;82(5):722\u2013724.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"e_1_3_5_30_1","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/1756-185X.14801","article-title":"Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: an open-label randomized controlled trial","volume":"26","author":"Khan MM","year":"2023","unstructured":"Khan MM, Ahmed S, Hasan Sajib MK, et al. Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: an open-label randomized controlled trial. Int J Rheum Dis. 2023;26(9):1729\u20131736.","journal-title":"Int J Rheum Dis"},{"issue":"18","key":"e_1_3_5_31_1","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis","volume":"137","author":"Zhang H","year":"2018","unstructured":"Zhang H, Watanabe R, Berry GJ, et al. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018;137(18):1934\u20131948.","journal-title":"Circulation"},{"issue":"3","key":"e_1_3_5_32_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/1744666X.2021.1890032","article-title":"Predicting the risk of relapse in polymyalgia rheumatica: novel insights","volume":"17","author":"Prieto-Pe\u00f1a D","year":"2021","unstructured":"Prieto-Pe\u00f1a D, Casta\u00f1eda S, Atienza-Mateo B, et al. Predicting the risk of relapse in polymyalgia rheumatica: novel insights. Expert Rev Clin Immunol. 2021;17(3):225\u2013232.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"e_1_3_5_33_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40744-020-00258-9","article-title":"Update on the safety profile of tofacitinib in rheumatoid arthritis from clinical trials to real-world studies: a narrative review","volume":"8","author":"\u00c1lvaro-Gracia JM","year":"2021","unstructured":"\u00c1lvaro-Gracia JM, Garc\u00eda-Llorente JF, Valderrama M, et al. Update on the safety profile of tofacitinib in rheumatoid arthritis from clinical trials to real-world studies: a narrative review. Rheumatol Ther. 2021;8(1):17\u201340.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"e_1_3_5_34_1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg SR","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u2013326.","journal-title":"N Engl J Med"}],"container-title":["Scandinavian Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03009742.2026.2722526","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/03009742.2026.2722526","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03009742.2026.2722526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:33:56Z","timestamp":1789554836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03009742.2026.2722526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":33,"alternative-id":["10.1080\/03009742.2026.2722526"],"URL":"https:\/\/doi.org\/10.1080\/03009742.2026.2722526","relation":{},"ISSN":["0300-9742","1502-7732"],"issn-type":[{"value":"0300-9742","type":"print"},{"value":"1502-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=irhe20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=irhe20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}